Repligen | RGEN - Operating Profit



Repligen reported $5.96M in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
Agilent USD 360M 60M Jul/2025
Align Technology USD 163.03M 31.93M Jun/2025
Bio Techne USD -23860000 62.57M Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Bristol-Myers Squibb USD 3.77B 366M Jun/2025
Bruker USD 11.9M 19.9M Jun/2025
Charles River Laboratories USD 132.33M 57.66M Jun/2025
Danaher USD 760M 523M Jun/2025
Dentsply International USD 111M 48M Jun/2025
Exact Sciences USD -2148000 93.86M Jun/2025
General Electric Aerospace USD 2.1B 356M Jun/2025
Henry Schein USD -2050000000 2.22B Jun/2025
Illumina USD 214M 83M Jun/2025
IQVIA Holdings USD 556M 64M Jun/2025
Mettler Toledo International USD 265.71M 63.77M Jun/2025
Myriad Genetics USD -29000000 10M Mar/2025
Pfizer USD 2.6B 1.06B Jun/2025
Repligen USD 5.96M 621K Jun/2025
Revvity USD 90.76M 18.53M Jun/2025
Standard Biotools USD -23700000 9.12M Jun/2025
Thermo Fisher Scientific USD 1.92B 200M Jun/2025
Waters USD 188.21M 36.47M Jun/2025
West Pharmaceutical Services USD 153.7M 46.7M Jun/2025